好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neurostatus e-Scoring Increases Quality of the Expanded Disability Status Scale (EDSS) Assessments: First Experience in a Phase 3 Clinical Trial with Siponimod in Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
(-)
112
Authors/Disclosures
Marcus D'Souza, MD (University-Hospital-Basel)
PRESENTER
Dr. D'Souza has nothing to disclose.
Roland John No disclosure on file
Heiko Rust No disclosure on file
No disclosure on file
No disclosure on file
Johannes Lorscheider The institution of Johannes Lorscheider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Johannes Lorscheider has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Johannes Lorscheider has received research support from Innosuisse - Swiss Innvation Ageny. The institution of Johannes Lorscheider has received research support from MSBase Foundation. The institution of Johannes Lorscheider has received research support from Novartis.
Shauna Gysin (Neurostatus Systems AG) No disclosure on file
Brian Hunter, PhD (Novartis Pharma AG) Brian Hunter has received personal compensation for serving as an employee of Novartis. Brian Hunter has received stock or an ownership interest from Novartis.
Erik Wallstroem, MD, PhD (Sanofi) Dr. Wallstroem has received personal compensation for serving as an employee of Sanofi. Dr. Wallstroem has stock in Sanofi. Dr. Wallstroem has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
Ludwig Kappos, MD, FAAN (RC2NB, University Hospital Basel) Dr. Kappos has nothing to disclose.